Business · Companies · 1 hr ago
AriBio-Linked Shares Fall After Alzheimer’s Drug Trial Results
AriBio-linked shares fell sharply in early trading on Nov.
17.
AriBio, a South Korean biotechnology company, is developing an oral treatment for Alzheimer’s disease.
The drug was tested in a global phase 3 clinical trial, a late-stage test of a treatment.
It met the trial’s pre-set primary target, but did not statistically prove a treatment effect in the overall patient group.
AriBio Lab shares were down 17.30% at 9:06 a.m., compared with the previous day.
The results show that meeting the trial’s main target did not establish a statistically significant effect across all patients.
Shares linked to South Korean biotechnology company AriBio fell sharply in early trading on November 17.
AriBio Lab shares were down 17.30% at 9:06 a.m. on the KOSDAQ market.
The decline followed news that AriBio’s oral Alzheimer’s treatment met its pre-set primary endpoint in a global Phase 3 trial.
The trial did not statistically demonstrate a treatment effect across the overall patient group.
- Who
- AriBio-linked stocks, including AriBio Lab shares.
- What
- The shares fell sharply after results from a Phase 3 trial of an oral Alzheimer’s treatment were reported.
- When
- November 17; AriBio Lab shares were down at 9:06 a.m.
- Where
- The KOSDAQ market.
- Why
- The treatment met its pre-set primary endpoint but did not statistically demonstrate an effect in the overall patient group.
This story does not have two clearly opposing sides.
AriBio’s oral Alzheimer’s treatment met its pre-set primary endpoint but did not statistically demonstrate an effect in the overall patient group.
AriBio Lab shares were down 17.30% on the KOSDAQ market.
- AriBio Lab share decline
- 17.30%
- Price change
- 1,005 won
- Market
- KOSDAQ
- Trial stage
- Global Phase 3
- Trial outcome
- Met pre-set primary endpoint; no statistically demonstrated effect in the overall patient group